Developmental Expression of Heme Degradation Genes in Zebrafish

Total Page:16

File Type:pdf, Size:1020Kb

Developmental Expression of Heme Degradation Genes in Zebrafish DEVELOPMENTAL EXPRESSION OF HEME DEGRADATION GENES IN ZEBRAFISH (DANIO RERIO) SUGGEST NOVEL ROLES IN HEMATOPOIESIS AND EYE DEVELOPMENT by ANDREW HOLOWIECKI MATTHEW J. JENNY, COMMITTEE CHAIR JOHN YODER CAROL DUFFY STEVE MARCUS PATRICK FRANTOM A DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Biological Sciences in the Graduate School of The University of Alabama TUSCALOOSA, ALABAMA 2015 Copyright Andrew Holowiecki 2015 ALL RIGHTS RESERVED ABSTRACT Heme is an important cofactor for numerous proteins, including hemoglobin used for oxygen transport. However, in its unbound form, heme is highly toxic and can perpetuate the formation of harmful reactive oxygen species (ROS). Thus, the heme degradation pathway, an evolutionarily conserved enzymatic pathway, facilitates the metabolism of heme into excretable by-products that may also have significant biological functions. Heme oxygenase (HO-1, HO-2) degrades heme into biliverdin (BV). Subsequently, BV is converted into the potent antioxidant bilirubin (BR) by biliverdin reductase (BVRa or BVRb). The ability of BR to efficiently quench ROS through a recycling reaction mediated by BVR is of great interest with strong medicinal implications. In support of this argument, individuals with slightly elevated levels of BR, a condition known as Gilbert’s syndrome, have lower incidences of diseases related to oxidative stress, such as cardiovascular disease. The goal of this research is to characterize the transcriptional regulation of genes involved in the heme degradation pathway. Chapter 2 provides a thorough characterization of expression of both sets of the HO-1 and HO-2 paralogs, as well as BVRa and BVRb, during normal development and in response to oxidative stress. It also provides new data on the sex-specific differences in expression of these genes under control and stressful conditions. The observed quantitative changes in divergent gene expression provide strong initial support for subfunction partitioning of the HO paralogs. Chapter 3 presents qualitative data on the expression patterns of HO-1a, BVRa and BVRb during development, conclusively demonstrating spatiotemporal patterns that are consistent with hematopoiesis. ii Additionally, in vivo promoter analysis demonstrates specific expression of HO-1a in eye lens epithelial cells during development. Finally, Chapter 4 presents functional data on the roles of GATA-1, the master regulator of erythroid development, and NRF2a, the master regulator of oxidative stress, on the spatiotemporal regulation of HO-1a, BVRa and BVRb during normal development and in response to oxidative stress. Furthermore, all three genes are expressed in developmental tissues that are highly sensitive to oxidative stress. In Chapter 5, we describe alternative experimental approaches, suggest future studies, and discuss these results in context with the current knowledge base. iii DEDICATION I dedicate this study to: My wife Kristy who has supported me through this, completion of this goal would not have been possible without your patience, love, and understanding. My daughter Lilly, who has been with me throughout this entire process, from birth she has looked over my data sets, critiqued my figures, and provided spot on advice on how to handle stress. My daughter Georgia, who entered the family half way through this project, your enthusiasm for life is contagious and inspirational. Your comedic timing is spot on. I love how you always listen to me prepare for seminars and repeat back “big science words”. My new son, Henry, I hope you will be proud of me. My mother, whom has set an example of what it means to work hard: first shift, second shift, or third shift for nearly 40 years at a steel plant. You continued to do this to help me during my time in graduate school and to help support me and my family. Clearly I could not have done this without you. My father, who passed away during my first year here, you instilled a strong sense of responsibility in me. I understand that it is a privilege to get to pursue an education. Thank you. My mother-in-law and father-in-law who have provided support and guidance: You have put in many miles to visit us down here. Thank you. iv LIST OF ABBREVIATIONS AND SYMBOLS AHR aryl hydrocarbon receptor ALM anterior lateral mesoderm AP-1 activator protein-1 ARNT aryl hydrocarbon receptor nuclear translocator proteins bHLH PAS basic-helix-loop-helix Per-ARNT-SIM protein family BVR biliverdin reductase BVRa biliverdin reductase alpha BVRb biliverdin reductase beta BV biliverdin BV-IXα alpha isomer of biliverdin BV-IX-β beta isomer of biliverdin BV-IXδ delta isomer of biliverdin BV-IXγ gamma isomer of biliverdin BR bilirubin BR-IXα alpha isomer of bilirubin BR-IX-β beta isomer of bilirubin bZip basic leucine zipper DNA binding domain Cd cadmium v cDNA complementary deoxyribonucleic acid CHT caudal hematopoietic tissue CMP’s common myelo-erythroid progenitors CRISPRs clustered regularly interspaced short palindromic repeats CUL3 cullin3 CYP1A cytochrome-p4501A DA dorsal aorta DDC duplication, degeneration, and complementation model DIG digoxigenin EDCs endocrine-disrupting chemicals eGFP enhanced green fluorescent protein EHT endothelial-to-hematopoietic transition EMPs erythomyeloid progenitors ETS E26 transformation-specific family FIH-1 factor inhibiting hypoxia inducible factor 1α GRPX glutathione peroxidase GRX glutathione reductase GSH reduced glutathione GSSG oxidized glutathione Hif1α hypoxia inducible factor-1α HO heme oxygenase HO-1 heme oxygenase 1 HO-2 heme oxygenase 2 vi HOOH hydrogen peroxide HRE hypoxia response element HSCs hematopoietic stem cells HSF heat shock factor HSP heat shock protein ICM intermediate cell mass IDHc cytosolic isocitrate dehydrogenase IDHm mitochondrial isocitrate dehydrogenase INRF2 inhibitor of nuclear factor erythroid 2-related factor 2 ISVs intersegmental veins Keap1 kelch-like ECH-associated protein 1 KOH potassium hydroxide Le lens LTZ lens transition zone mCherry red fluorescent protein (“m” monomer conformation) MAPK mitogen-activated protein kinase MEPS Mass Embryo Production System MO morpholino MTF-1 metal-regulatory transcription factor 1 NAD nicotinamide adenine dinucleotide NADH nicotinamide adenine dinucleotide (reduced form) NADP nicotinamide adenine dinucleotide phosphate NADPH nicotinamide adenine dinucleotide phosphate (reduced form) vii NES nuclear export signal NLS nuclear localization signal NFκB nuclear factor–κB NNT nicatinamide nucleotide transhydrogenase NRF2 nuclear factor erythroid 2-related factor 2 OD o-dianisidine OP olfactory placode PBI posterior blood island PBS phosphate buffered saline PBST phosphate buffered saline with 0.1% tween PCBs polychlorinated biphenols PFA paraformaldehyde PL posterior lens PLM posterior lateral mesoderm PMBC primordial midbrain channel PPP pentose phosphate pathway PQQ pyrroloquinoline quinone PRDX peroxiredoxin qPCR quantitative polymerase chain reaction RBC red blood cell ROS reactive oxygen species RPE retinal pigment epithelium SOD superoxide dismutase viii S/T/K serine, threonine, tyrosine kinase TALENs transcription activator-like effector nucleases tBHQ tert-butylhydroquinone TCDD dioxin VEGF vascular endothelial growth factor UROD uroporphyrinogen decarboxylase WBC’s white blood cell XRE xenobiotic response element ix ACKNOWLEDGEMENTS First I would like to thank Dr. Matthew Jenny for taking a chance on me, providing guidance, and continually challenging me. Additionally, I would like to thank my committee members: Your dedication to teaching in the classroom played a big part in my success. Many of my ideas originated from classroom discussions. Finally, I would like to acknowledge members of the Jenny lab. x CONTENTS ABSTRACT .................................................................................................................................... ii DEDICATION ............................................................................................................................... iv LIST OF ABREVIATIONS AND SYMBOLS ...............................................................................v ACKNOWLEDGEMENTS .............................................................................................................x LIST OF TABLES ....................................................................................................................... xiv LIST OF FIGURES .......................................................................................................................xv 1 UTILIZING ZEBRAFISH (DANIO RERIO) AS A DEVELOPMENTAL AND TOXICOLOGICAL MODEL ........................................................1 1.1 Introduction ...............................................................................................................................1 1.2 Zebrafish as a Developmental, Toxicological, and Disease model ..........................................2 1.3 The Zebrafish Genome and Subfunction Partitioning ..............................................................4 1.4 Oxidative Stress and Redox Signaling ......................................................................................5 1.5 Antioxidant Defense Mechanisms ............................................................................................6 1.6 Transcriptional Regulators of Stress Response and their Roles in Development ....................8 1.7 NRF2 is the Master Regulator of Oxidative Stress ...................................................................8
Recommended publications
  • 1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental
    Page 1 of 255 Diabetes Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy Oliver J. Freeman1,2, Richard D. Unwin2,3, Andrew W. Dowsey2,3, Paul Begley2,3, Sumia Ali1, Katherine A. Hollywood2,3, Nitin Rustogi2,3, Rasmus S. Petersen1, Warwick B. Dunn2,3†, Garth J.S. Cooper2,3,4,5* & Natalie J. Gardiner1* 1 Faculty of Life Sciences, University of Manchester, UK 2 Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK 3 Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK 4 School of Biological Sciences, University of Auckland, New Zealand 5 Department of Pharmacology, Medical Sciences Division, University of Oxford, UK † Present address: School of Biosciences, University of Birmingham, UK *Joint corresponding authors: Natalie J. Gardiner and Garth J.S. Cooper Email: [email protected]; [email protected] Address: University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, United Kingdom Telephone: +44 161 275 5768; +44 161 701 0240 Word count: 4,490 Number of tables: 1, Number of figures: 6 Running title: Metabolic dysfunction in diabetic neuropathy 1 Diabetes Publish Ahead of Print, published online October 15, 2015 Diabetes Page 2 of 255 Abstract High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However our understanding of the molecular mechanisms which cause the marked distal pathology is incomplete. Here we performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN.
    [Show full text]
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal
    5 6 6 5 . 4 2 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C C C C C C R R R R R R R R R R R R R R R R R R R R B , B B B B B B B B B B B B B B B B B B B , 9 , , , , 4 , , 3 0 , , , , , , , , 6 2 , , 5 , 0 8 6 4 , 7 5 7 0 2 8 9 1 3 3 3 1 1 7 5 0 4 1 4 0 7 1 0 2 0 6 7 8 0 2 5 7 8 0 3 8 5 4 9 0 1 0 8 8 3 5 6 7 4 7 9 5 2 1 1 8 2 2 1 7 9 6 2 1 7 1 1 0 4 5 3 5 8 9 1 0 0 4 2 5 0 8 1 4 1 6 9 0 0 6 3 6 9 1 0 9 0 3 8 1 3 5 6 3 6 0 4 2 6 1 0 1 2 1 9 9 7 9 5 7 1 5 8 9 8 8 2 1 9 9 1 1 1 9 6 9 8 9 7 8 4 5 8 8 6 4 8 1 1 2 8 6 2 7 9 8 3 5 4 3 2 1 7 9 5 3 1 3 2 1 2 9 5 1 1 1 1 1 1 5 9 5 3 2 6 3 4 1 3 1 1 4 1 4 1 7 1 3 4 3 2 7 6 4 2 7 2 1 2 1 5 1 6 3 5 6 1 3 6 4 7 1 6 5 1 1 4 1 6 1 7 6 4 7 e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m
    [Show full text]
  • Supplementary Table 1 List of 335 Genes Differentially Expressed Between Primary (P) and Metastatic (M) Tumours
    Supplementary Table 1 List of 335 genes differentially expressed between primary (P) and metastatic (M) tumours Spot ID I.M.A.G.E. UniGene Symbol Name Clone ID Cluster 296529 296529 In multiple clusters 731356 731356 Hs.140452 M6PRBP1 mannose-6-phosphate receptor binding protein 1 840942 840942 Hs.368409 HLA-DPB1 major histocompatibility complex, class II, DP beta 1 142122 142122 Hs.115912 AFAP actin filament associated protein 1891918 1891918 Hs.90073 CSE1L CSE1 chromosome segregation 1-like (yeast) 1323432 1323432 Hs.303154 IDS iduronate 2-sulfatase (Hunter syndrome) 788566 788566 Hs.80296 PCP4 Purkinje cell protein 4 591281 591281 Hs.80680 MVP major vault protein 815530 815530 Hs.172813 ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 825312 825312 Hs.246310 ATP5J ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6 784830 784830 Hs.412842 C10orf7 chromosome 10 open reading frame 7 840878 840878 Hs.75616 DHCR24 24-dehydrocholesterol reductase 669443 669443 Hs.158195 HSF2 heat shock transcription factor 2 2485436 2485436 Data not found 82903 82903 Hs.370937 TAPBP TAP binding protein (tapasin) 771258 771258 Hs.85258 CD8A CD8 antigen, alpha polypeptide (p32) 85128 85128 Hs.8986 C1QB complement component 1, q subcomponent, beta polypeptide 41929 41929 Hs.39252 PICALM phosphatidylinositol binding clathrin assembly protein 148469 148469 Hs.9963 TYROBP TYRO protein tyrosine kinase binding protein 415145 415145 Hs.1376 HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 810017 810017 Hs.179657 PLAUR plasminogen activator,
    [Show full text]
  • Supplementary File 2A Revised
    Supplementary file 2A. Differentially expressed genes in aldosteronomas compared to all other samples, ranked according to statistical significance. Missing values were not allowed in aldosteronomas, but to a maximum of five in the other samples. Acc UGCluster Name Symbol log Fold Change P - Value Adj. P-Value B R99527 Hs.8162 Hypothetical protein MGC39372 MGC39372 2,17 6,3E-09 5,1E-05 10,2 AA398335 Hs.10414 Kelch domain containing 8A KLHDC8A 2,26 1,2E-08 5,1E-05 9,56 AA441933 Hs.519075 Leiomodin 1 (smooth muscle) LMOD1 2,33 1,3E-08 5,1E-05 9,54 AA630120 Hs.78781 Vascular endothelial growth factor B VEGFB 1,24 1,1E-07 2,9E-04 7,59 R07846 Data not found 3,71 1,2E-07 2,9E-04 7,49 W92795 Hs.434386 Hypothetical protein LOC201229 LOC201229 1,55 2,0E-07 4,0E-04 7,03 AA454564 Hs.323396 Family with sequence similarity 54, member B FAM54B 1,25 3,0E-07 5,2E-04 6,65 AA775249 Hs.513633 G protein-coupled receptor 56 GPR56 -1,63 4,3E-07 6,4E-04 6,33 AA012822 Hs.713814 Oxysterol bining protein OSBP 1,35 5,3E-07 7,1E-04 6,14 R45592 Hs.655271 Regulating synaptic membrane exocytosis 2 RIMS2 2,51 5,9E-07 7,1E-04 6,04 AA282936 Hs.240 M-phase phosphoprotein 1 MPHOSPH -1,40 8,1E-07 8,9E-04 5,74 N34945 Hs.234898 Acetyl-Coenzyme A carboxylase beta ACACB 0,87 9,7E-07 9,8E-04 5,58 R07322 Hs.464137 Acyl-Coenzyme A oxidase 1, palmitoyl ACOX1 0,82 1,3E-06 1,2E-03 5,35 R77144 Hs.488835 Transmembrane protein 120A TMEM120A 1,55 1,7E-06 1,4E-03 5,07 H68542 Hs.420009 Transcribed locus 1,07 1,7E-06 1,4E-03 5,06 AA410184 Hs.696454 PBX/knotted 1 homeobox 2 PKNOX2 1,78 2,0E-06
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Haem Oxygenase Is Synthetically Lethal with the Tumour Suppressor Fumarate Hydratase
    LETTER doi:10.1038/nature10363 Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase Christian Frezza1, Liang Zheng1, Ori Folger2, Kartik N. Rajagopalan3, Elaine D. MacKenzie1, Livnat Jerby2, Massimo Micaroni4, Barbara Chaneton1, Julie Adam5, Ann Hedley1, Gabriela Kalna1, Ian P. M. Tomlinson6, Patrick J. Pollard5, Dave G. Watson7, Ralph J. Deberardinis3, Tomer Shlomi8*, Eytan Ruppin2,9* & Eyal Gottlieb1 Fumarate hydratase (FH) is an enzyme of the tricarboxylic acid majority of fumarate was unlabelled (m10), indicating that glucose is cycle (TCA cycle) that catalyses the hydration of fumarate into a minor source of carbon for the TCA cycle in both Fh1fl/fl and Fh12/2 malate. Germline mutations of FH are responsible for hereditary cells (Fig. 1e). On the other hand, when cells were incubated with 13C- leiomyomatosis and renal-cell cancer (HLRCC)1. It has previously glutamine most of the fumarate was labelled (Fig. 1f). In Fh12/2 cells been demonstrated that the absence of FH leads to the accumula- cultured with uniformly labelled glutamine (Fig. 1f), the vast majority of tion of fumarate, which activates hypoxia-inducible factors (HIFs) the labelled fumarate contained all four carbon atoms derived from at normal oxygen tensions2–4. However, so far no mechanism that glutamine (m14). By contrast, in Fh1fl/fl cells, the fumarate pool con- explains the ability of cells to survive without a functional TCA tained substantial fractions of molecules with fewer than four 13C atoms cycle has been provided. Here we use newly characterized genetically due to processing of fumarate beyond the Fh1 step. The lack of these modified kidney mouse cells in which Fh1 has been deleted, and products in Fh12/2 cells confirms that no accessory pathway exists in apply a newly developed computer model of the metabolism of these these cells to circumvent the loss of Fh1 enzymatic activity, indicating a cells to predict and experimentally validate a linear metabolic path- true blockade of the cycle.
    [Show full text]
  • Biliverdin Reductase: a Major Physiologic Cytoprotectant
    Biliverdin reductase: A major physiologic cytoprotectant David E. Baran˜ ano*, Mahil Rao*, Christopher D. Ferris†, and Solomon H. Snyder*‡§¶ Departments of *Neuroscience, ‡Pharmacology and Molecular Sciences, and §Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; and †Department of Medicine, Division of Gastroenterology, C-2104 Medical Center North, Vanderbilt University Medical Center, Nashville, TN 37232-2279 Contributed by Solomon H. Snyder, October 16, 2002 Bilirubin, an abundant pigment that causes jaundice, has long hypothesize that bilirubin acts in a catalytic fashion whereby lacked any clear physiologic role. It arises from enzymatic reduction bilirubin oxidized to biliverdin is rapidly reduced back to bili- by biliverdin reductase of biliverdin, a product of heme oxygenase rubin, a process that could readily afford 10,000-fold amplifica- activity. Bilirubin is a potent antioxidant that we show can protect tion (13). Here we establish that a redox cycle based on BVRA cells from a 10,000-fold excess of H2O2. We report that bilirubin is activity provides physiologic cytoprotection as BVRA depletion a major physiologic antioxidant cytoprotectant. Thus, cellular de- exacerbates the formation of reactive oxygen species (ROS) and pletion of bilirubin by RNA interference markedly augments tissue augments cell death. levels of reactive oxygen species and causes apoptotic cell death. Depletion of glutathione, generally regarded as a physiologic Methods antioxidant cytoprotectant, elicits lesser increases in reactive ox- All chemicals were obtained from Sigma unless otherwise ygen species and cell death. The potent physiologic antioxidant indicated. actions of bilirubin reflect an amplification cycle whereby bilirubin, acting as an antioxidant, is itself oxidized to biliverdin and then Cell Culture and Viability Measurements.
    [Show full text]
  • ©Ferrata Storti Foundation
    Original Articles T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response Peter Van Loo,1,2,3 Thomas Tousseyn,4 Vera Vanhentenrijk,4 Daan Dierickx,5 Agnieszka Malecka,6 Isabelle Vanden Bempt,4 Gregor Verhoef,5 Jan Delabie,6 Peter Marynen,1,2 Patrick Matthys,7 and Chris De Wolf-Peeters4 1Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium; 2Department of Human Genetics, K.U.Leuven, Leuven, Belgium; 3Bioinformatics Group, Department of Electrical Engineering, K.U.Leuven, Leuven, Belgium; 4Department of Pathology, University Hospitals K.U.Leuven, Leuven, Belgium; 5Department of Hematology, University Hospitals K.U.Leuven, Leuven, Belgium; 6Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway, and 7Department of Microbiology and Immunology, Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium Citation: Van Loo P, Tousseyn T, Vanhentenrijk V, Dierickx D, Malecka A, Vanden Bempt I, Verhoef G, Delabie J, Marynen P, Matthys P, and De Wolf-Peeters C. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolero- genic host immune response. Haematologica. 2010;95:440-448. doi:10.3324/haematol.2009.009647 The Online Supplementary Tables S1-5 are in separate PDF files Supplementary Design and Methods One microgram of total RNA was reverse transcribed using random primers and SuperScript II (Invitrogen, Merelbeke, Validation of microarray results by real-time quantitative Belgium), as recommended by the manufacturer. Relative reverse transcriptase polymerase chain reaction quantification was subsequently performed using the compar- Ten genes measured by microarray gene expression profil- ative CT method (see User Bulletin #2: Relative Quantitation ing were validated by real-time quantitative reverse transcrip- of Gene Expression, Applied Biosystems).
    [Show full text]
  • The Kinesin Spindle Protein Inhibitor Filanesib Enhances the Activity of Pomalidomide and Dexamethasone in Multiple Myeloma
    Plasma Cell Disorders SUPPLEMENTARY APPENDIX The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma Susana Hernández-García, 1 Laura San-Segundo, 1 Lorena González-Méndez, 1 Luis A. Corchete, 1 Irena Misiewicz- Krzeminska, 1,2 Montserrat Martín-Sánchez, 1 Ana-Alicia López-Iglesias, 1 Esperanza Macarena Algarín, 1 Pedro Mogollón, 1 Andrea Díaz-Tejedor, 1 Teresa Paíno, 1 Brian Tunquist, 3 María-Victoria Mateos, 1 Norma C Gutiérrez, 1 Elena Díaz- Rodriguez, 1 Mercedes Garayoa 1* and Enrique M Ocio 1* 1Centro Investigación del Cáncer-IBMCC (CSIC-USAL) and Hospital Universitario-IBSAL, Salamanca, Spain; 2National Medicines Insti - tute, Warsaw, Poland and 3Array BioPharma, Boulder, Colorado, USA *MG and EMO contributed equally to this work ©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2017.168666 Received: March 13, 2017. Accepted: August 29, 2017. Pre-published: August 31, 2017. Correspondence: [email protected] MATERIAL AND METHODS Reagents and drugs. Filanesib (F) was provided by Array BioPharma Inc. (Boulder, CO, USA). Thalidomide (T), lenalidomide (L) and pomalidomide (P) were purchased from Selleckchem (Houston, TX, USA), dexamethasone (D) from Sigma-Aldrich (St Louis, MO, USA) and bortezomib from LC Laboratories (Woburn, MA, USA). Generic chemicals were acquired from Sigma Chemical Co., Roche Biochemicals (Mannheim, Germany), Merck & Co., Inc. (Darmstadt, Germany). MM cell lines, patient samples and cultures. Origin, authentication and in vitro growth conditions of human MM cell lines have already been characterized (17, 18). The study of drug activity in the presence of IL-6, IGF-1 or in co-culture with primary bone marrow mesenchymal stromal cells (BMSCs) or the human mesenchymal stromal cell line (hMSC–TERT) was performed as described previously (19, 20).
    [Show full text]
  • Recombinant Human Biliverdin Reductase B/BLVRB
    Recombinant Human Biliverdin Reductase B/BLVRB Catalog Number: 6568-BR DESCRIPTION Source E. coli­derived human Biliverdin Reductase B/BLVRB protein Ala2­Gln206, with an N­terminal Met and 6­His tag Accession # P30043 N­terminal Sequence N­terminus confirmed by detection of His tag using Western analysis. Analysis Predicted Molecular 23 kDa Mass SPECIFICATIONS SDS­PAGE 23­25 kDa, reducing conditions Activity Measured by the reduction of riboflavin 5'­monophosphate (FMN) using NADPH as the cofactor. The specific activity is >225 pmol/min/μg, as measured under the described conditions. Endotoxin Level <1.0 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS­PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, Brij and Glycerol. See Certificate of Analysis for details. Activity Assay Protocol Materials l Assay Buffer: 100 mM Sodium Acetate, pH 5.0 l Recombinant Human Biliverdin Reductase B/BLVRB (rhBLVRB) (Catalog # 6568­BR) l Riboflavin 5’­monophosphate sodium salt dihydrate (FMN) (Sigma, Catalog # F6750), 10 mM in deionized water l β­Nicotinamide adenine dinucleotide phosphate reduced, tetrasodium salt (β­NADPH) (Sigma, Catalog # N7505), 10 mM in deionized water l UV Plate (Costar, Catalog # 3635) l Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent Assay 1. Dilute rhBLVRB to 40 ng/μL in Assay Buffer. 2. Prepare a Reaction Mixture by combining FMN and β­NADPH in Assay Buffer to a concentration of 400 μM for each. 3. Load 50 μL of 40 ng/μL rhBLVRB into the microplate, and start the reaction by adding 50 μL of Reaction Mixture.
    [Show full text]